stem cells spinal cord injury

Stem cell good news, cool pubs, & some hype on living robots

Would-living-robots-be-good-news-Purported-living-robots-made-from-frog-stem-cells-which-are-called-22xenobots22.-This-has-been-hyped

Over time I seem to collect more upbeat stories about stem cells and regenerative medicine as well as cool publications  so today’s “good news” post is a collection of these kinds of things plus one example of huge science hype. Here’s a list of past such upbeat posts. The preclinical good news in rats from …

Stem cell good news, cool pubs, & some hype on living robots Read More »

Several more reports of spinal tumors from nasal stem cell transplants

CMAJ-2019-Woodworth-et-al.-Figure-1-spinal-tumor-imaging-after-nasal-stem-cell-transplant

At least four cases of spinal tumors have now been reported following experimental nasal stem cell transplants for paralysis. There’s some risk of tumor development with just about any stem cell transplant, but risks are higher with experimental injections of unproven stem cells. Whill risks of tumor formation come along even with standard bone marrow …

Several more reports of spinal tumors from nasal stem cell transplants Read More »

Japan stem cell clinical studies rapidly piling up

Shibata-et-al.-Cell-reports-2018-corneal-structures-made-from-hIPSCs

Japan is a leader in stem cell and regenerative medicine research, and in particular in clinical translation toward the bedside. Induced pluripotent stem cell (IPSC)-based investigational therapies are rightly an area of focus in Japan given their invention by Nobel Laureate Shinya Yamanaka. Small clinical studies based on IPSC have been initiated there for several …

Japan stem cell clinical studies rapidly piling up Read More »

Grading 3 stem cell media reports on clinical science: vision, MS, & paralysis

Rosenzweig-et-al-Nature-Medicine-2018-part-of-Fig.-1

What is stem cell media? When us scientists hear the phrase “stem cell media” we usually think about the liquid food that we feed our stem cells in the lab, which resembles a kind of nutrient-rich Kool-aid, but another kind of stem cell media consists of the news coverage of stem cells. This other kind …

Grading 3 stem cell media reports on clinical science: vision, MS, & paralysis Read More »

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte

VC-01-post-implant-final1-e1503703572933, viacyte

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a …

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »

Good stem cell news on trials, FDA, cool new papers & more

Pericyte-paper

In the whirlwind that is the stem cell and regenerative medicine world, there are many concerning things that need attention, but also good stuff happens too and this post focuses on the positive. The Asterias spinal cord injury clinical trial, a phase 1/2a trial called SCiStar, continues to make encouraging news with a clean safety profile …

Good stem cell news on trials, FDA, cool new papers & more Read More »

Asterias interview: stem cell spinal cord injury trials advance

Asterias

Recently I had the opportunity to talk with the leadership of Asterias, a California biotech doing exciting clinical research using stem cells as the basis for treatment of spinal cord injury. The interview covers the past (Geron patients), present, and future. I spoke with Asterias President and CEO Stephen Cartt and CMO Edward Wirth. How …

Asterias interview: stem cell spinal cord injury trials advance Read More »

End of line for StemCells Inc., pioneering & controversial stem cell biotech

stemcellsinc-logo

A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for …

End of line for StemCells Inc., pioneering & controversial stem cell biotech Read More »